Paul Tudor Jones Inhibrx, Inc. Transaction History

Tudor Investment Corp Et Al

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $48,299 - $126,578	-3,331 Reduced 15.34%	18,379 $698,000
Q3 2023 Nov 15, 2023	BUY	$15.75 - $26.31 $341,932 - $571,190	21,710 New	21,710 $398,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $16,987 - $36,278	1,467 Added 7.77%	20,358 $365,000
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $25,057 - $74,289	2,941 Added 18.44%	18,891 $214,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $317,245 - $688,721	15,950 New	15,950 $355,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.